Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2710 results

Pulse Update / Apr 04, 2024

Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
Press Release / Mar 22, 2024

Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)

Positive CHMP opinion based on robust Phase III data, including APPLY-PNH, demonstrating superior hemoglobin improvement in the absence of transfusions with Fabhalta compared to anti-C5 therapy1-5 If…
Non-profit partnering for positive, sustainable social change
Donations
Media Library / Mar 01, 2024

Novartis radioligand therapy (RLT) manufacturing facility
Media Library / Mar 01, 2024

Radioligand therapy (RLT) production line
Media Library / Mar 01, 2024

Refrigeration room at a Novartis radioligand therapy (RLT) manufacturing facility
Media Library / Mar 01, 2024

Specialized equipment for the manufacture of radioligand therapy (RLT)
Media Library / Mar 01, 2024

Quality control for environmental monitoring in radioligand therapy (RLT) manufacturing
Press Release / Mar 05, 2024

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

Shareholders approve 27th consecutive dividend increase to CHF 3.30 (+3.1%) per share for 2023; representing a 3.7% yield1 and approximately 58% payout of free cash flowShareholders confirm Joerg…